The Medical Letter on Drugs and Therapeutics
A Once-Daily Combination Tablet (Atripla) for HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Atripla (Gilead/Bristol-Myers Squibb) is the first oncedaily, single-tablet combination of 3 antiretroviral drugs for treatment of HIV infection. Each tablet contains 600 mg of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva), 200 mg of the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (Emtriva), and 300 mg of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir DF (Viread). These drugs have been recommended for use together, if resistance testing confirms susceptibility, as an initial regimen of choice for treatment-naïve patients.1-3

CLINICAL STUDY — There have been no clinical trials with the fixed-dose combination tablet. A randomized, open-label, noninferiority study in 517 treatment-naïve HIV patients compared a regimen of efavirenz, emtricitabine, and tenofovir (in the same doses used ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Once-Daily Combination Tablet (Atripla) for HIV
Article code: 1244b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian